AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated March 10, 2026.
X4 Pharmaceuticals is a biopharmaceutical company focused on developing therapeutic treatments for rare diseases. Leveraging state-of-the-art technology, X4 aims to address unmet medical needs, providing innovative solutions for complex health issues. The company's focus areas include rare diseases and immune system health, a niche but impactful market with significant growth potential.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | March 10 Price is up by 6% in the last 24h. |
|
X4 Pharmaceuticals | March 9 Price is up by 6.4% in the last 24h. |
|
X4 Pharmaceuticals | February 26 Price is down by -6.1% in the last 24h. |
|
X4 Pharmaceuticals | February 24 Price is up by 6.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,540 | Sign up | Sign up | Sign up |
| X Followers | 1,085 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 79 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $4.66 |
| Target Price | Sign up |
| Volume | 590,519 |
| Market Cap | $329M |
| Year Range | $1.42 - $4.66 |
| Dividend Yield | 0% |
| PE Ratio | 0.67 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst AttentionMarch 9 - Yahoo Entertainment |
|
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2 - GlobeNewswire |
|
 |
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptFebruary 16 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.8M | 350,000 | 1.4M | -30M | -27M | -0.690 |
| Q2 '25 | 2M | 330,000 | 1.6M | -26M | -23M | -3.470 |
| Q1 '25 | 29M | 4.7M | 24M | 280,000 | 3M | 0.040 |
| Q4 '24 | 1.4M | 300,000 | 1.1M | -40M | -37M | -0.200 |
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | -0.180 |
Insider Transactions View All
| Craig Adam R filed to buy 376,087 shares at $2.9. October 27 '25 |
| Baldry Mark filed to buy 25,337 shares at $2.5. May 20 '25 |
| Arbet-Engels Christophe filed to sell 14,207 shares at $0.5. January 27 '25 |
| DiBiase Mary filed to sell 490,980 shares at $0.5. January 27 '25 |
| Baldry Mark filed to sell 94,123 shares at $0.5. January 27 '25 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - X4 Pharmaceuticals
The Market Cap of X4 Pharmaceuticals is $329M.
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 0.67.
Currently, the price of one share of X4 Pharmaceuticals stock is $4.66.
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
